Chong Kun Dang: "Lipirou 20mg Shows Superior Efficacy and Cost-Effectiveness"

[Asia Economy Reporter Cho Hyun-ui] Chong Kun Dang announced on the 27th that the 20mg product of the dyslipidemia treatment drug 'Lipirou' showed excellent efficacy and cost-effectiveness.

Chong Kun Dang recently presented these clinical trial results at the American Heart Association (AHA) Annual Scientific Sessions held online. This study was conducted to verify the efficacy and cost-effectiveness of Lipirou 10mg and 20mg in Korean patients with high-risk hypercholesterolemia.

The research team led by Professor Kim Jin-won of the Department of Cardiology at Korea University College of Medicine divided 237 patients classified as high-risk and very high-risk according to the Korean dyslipidemia guidelines into two groups, administering Lipirou 10mg and 20mg respectively for 12 weeks. Afterwards, they evaluated the levels of low-density lipoprotein cholesterol (LDL-C), which is harmful to the body, and conducted a cost-effectiveness assessment.

The study results showed that the LDL-C levels in the 10mg group decreased by 33.5% after 12 weeks. In the 20mg group, LDL-C levels decreased by 42.4%, indicating that cholesterol levels were lowered in both groups.

In the secondary endpoint of cost-effectiveness evaluation, the average cost-effectiveness ratio (ACER) for the 10mg dose was 2,604 KRW per 1% reduction in cholesterol levels. For the 20mg dose, it was 2,074 KRW, confirming it was more than 20% cheaper.

A Chong Kun Dang official stated, "This study is significant in that it simultaneously evaluated the efficacy and cost-effectiveness by dosage in domestic high-risk patients," adding, "The results of this study provide another standard for drug prescription in the treatment of dyslipidemia patients."

This content was produced with the assistance of AI translation services.